https://www.pharmaradar360.com/article/gc-biopharma-targets-300m-u-s-alglio-sales-expands-korea-led-biotech-push-chosun-fcb1e970c2f4ccf1Pharma Surgeen2026-07-25T21:01:00.000ZGC Biopharma targets $300m U.S. Alglio sales, expands Korea-led biotech push - CHOSUNBIZhttps://www.pharmaradar360.com/article/etfs-investing-in-rtw-biotech-opportunities-ltd-usd-stocks-7acab5e94a8204a3Pharma Surgeen2026-07-25T19:06:04.000ZETFs Investing in RTW Biotech Opportunities Ltd USD Stockshttps://www.pharmaradar360.com/article/200-tariff-threat-on-us-generic-drug-imports-what-it-means-for-india-a6fb1a93cf90eca2Pharma Surgeen2026-07-25T19:04:27.000Z200% tariff threat on US generic drug imports: What it means for Indiahttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-cabio-biotech-wuhan-co-ltd-class-a-sse-688089-308065a9681f27d6Pharma Surgeen2026-07-25T18:46:12.000ZPrice to earnings forward of CABIO Biotech (Wuhan) Co. Ltd. Class A – SSE:688089https://www.pharmaradar360.com/article/sopan-pharmaceutical-ipo-analysis-sopan-pharmaceutical-ipo-new-ipo-opening-ipo-c-5c73c5eb1872d5f0Pharma Surgeen2026-07-25T18:07:20.000ZSopan Pharmaceutical Ipo Analysis | Sopan Pharmaceutical Ipo | New Ipo Opening | Ipo Conor Mcgregor (wkIR5koJkM)https://www.pharmaradar360.com/article/diabetes-drug-may-help-repair-liver-damage-f0aba38046f6eed4Pharma Surgeen2026-07-25T17:24:25.000ZDiabetes drug may help repair liver damagehttps://www.pharmaradar360.com/article/protect-pharmaceutical-corp-revenue-breakdown-otc-prtt-603942ed1bba7526Pharma Surgeen2026-07-25T16:52:01.000ZProtect Pharmaceutical Corp Revenue Breakdown – OTC:PRTThttps://www.pharmaradar360.com/article/zhejiang-huahai-pharmaceutical-co-ltd-class-a-revenue-breakdown-sse-600521-1fb8a3f83bfd17eaPharma Surgeen2026-07-25T16:51:09.000ZZhejiang Huahai Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SSE:600521https://www.pharmaradar360.com/article/us-generic-drug-tariff-to-have-limited-near-term-impact-on-indian-firms-report-1a62bdf0c6c85f2fPharma Surgeen2026-07-25T16:08:46.000ZUS generic drug tariff to have limited near-term impact on Indian firms: Reporthttps://www.pharmaradar360.com/article/reyon-pharmaceutical-co-ltd-revenue-breakdown-krx-102460-d8b74db599fb2bb5Pharma Surgeen2026-07-25T15:49:24.000ZReyon Pharmaceutical Co., Ltd. Revenue Breakdown – KRX:102460https://www.pharmaradar360.com/article/murata-stock-and-2-japanese-shares-investors-are-watching-for-cash-flow-value-29f133474283b709Pharma Surgeen2026-07-25T15:24:54.000ZMurata Stock And 2 Japanese Shares Investors Are Watching For Cash Flow Valuehttps://www.pharmaradar360.com/article/a-single-dose-reversed-autism-like-symptoms-in-adult-mice-within-hours-662cabf608e1e559Pharma Surgeen2026-07-25T15:09:37.000ZA single dose reversed autism-like symptoms in adult mice within hourshttps://www.pharmaradar360.com/article/superagers-keep-youthful-memories-but-their-dna-does-not-explain-why-204138ece07ea6e6Pharma Surgeen2026-07-25T14:41:54.000ZSuperagers keep youthful memories but their DNA does not explain whyhttps://www.pharmaradar360.com/article/the-bull-case-for-takeda-pharmaceutical-tse-4502-could-change-following-new-zaso-f16f3d9afc486b16Pharma Surgeen2026-07-25T14:27:38.000ZThe Bull Case For Takeda Pharmaceutical (TSE:4502) Could Change Following New Zasocitinib Phase 3 Psoriasis Datahttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-beijing-sl-pharmaceutical-co-ltd-class-a-s-8e1e11525c8ae90aPharma Surgeen2026-07-25T14:18:35.000ZEnterprise value to EBITDA forward of Beijing SL Pharmaceutical Co. Ltd. Class A – SZSE:002038https://www.pharmaradar360.com/article/price-to-sales-forward-of-shanghai-xiao-fang-pharmaceutical-co-ltd-class-a-sse-6-1bd0fdfc3df9547cPharma Surgeen2026-07-25T13:36:49.000ZPrice to sales forward of Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A – SSE:603207https://www.pharmaradar360.com/article/commercial-trade-s-expanding-mandate-from-product-movement-to-commercial-perform-e92b28cf65a85178Pharma Surgeen2026-07-25T13:03:37.000ZCommercial Trade's Expanding Mandate: From Product Movement to Commercial Performancehttps://www.pharmaradar360.com/article/chinese-ambassador-to-zimbabwe-zhou-ding-visits-china-aided-zimbabwe-national-ph-c64612205e623697Pharma Surgeen2026-07-25T12:59:41.000ZChinese Ambassador to Zimbabwe, Zhou Ding, visits China-aided Zimbabwe National Pharmaceutical Warehousehttps://www.pharmaradar360.com/article/iran-india-agree-to-facilitate-medical-and-pharmaceutical-cooperation-at-brics-m-48352d9cbb78f6a0Pharma Surgeen2026-07-25T12:55:23.000ZIran, India agree to facilitate medical and pharmaceutical cooperation at BRICS meetinghttps://www.pharmaradar360.com/article/merck-unveils-early-global-access-plan-for-monthly-hiv-prevention-pill-ahead-of-5047f67ab361ada1Pharma Surgeen2026-07-25T12:51:35.000ZMerck unveils early global access plan for monthly HIV prevention pill ahead of phase 3 completionhttps://www.pharmaradar360.com/article/us-court-rules-fda-abortion-pill-restrictions-unlawful-orders-review-of-mifepris-be2f353462c2124ePharma Surgeen2026-07-25T12:44:26.000ZUS Court Rules FDA Abortion Pill Restrictions Unlawful, Orders Review of Mifepristone Ruleshttps://www.pharmaradar360.com/article/argenx-a-biotech-powerhouse-poised-for-broad-expansion-58dc8f43049008f8Pharma Surgeen2026-07-25T12:11:12.000ZArgenx: A Biotech Powerhouse Poised for Broad Expansionhttps://www.pharmaradar360.com/article/rtw-biotech-opportunities-ltd-usd-revenue-breakdown-lse-rtw-96561b961e553bc4Pharma Surgeen2026-07-25T12:08:05.000ZRTW Biotech Opportunities Ltd USD Revenue Breakdown – LSE:RTWhttps://www.pharmaradar360.com/article/the-trump-administration-s-best-healthcare-idea-isn-t-the-one-getting-attention-81a296db8ec44463Pharma Surgeen2026-07-25T12:01:04.000ZThe Trump administration’s best healthcare idea isn’t the one getting attentionhttps://www.pharmaradar360.com/article/what-does-eric-green-s-retirement-mean-for-west-pharmaceutical-services-3097be13a03bbaf0Pharma Surgeen2026-07-25T11:56:16.000ZWhat Does Eric Green's Retirement Mean for West Pharmaceutical Serviceshttps://www.pharmaradar360.com/article/oral-glp-1-drugs-may-quiet-the-brain-s-food-craving-circuit-11c1fce8d3acbc92Pharma Surgeen2026-07-25T11:34:04.000ZOral GLP-1 drugs may quiet the brain’s food craving circuithttps://www.pharmaradar360.com/article/why-is-cathie-wood-shifting-from-tech-to-biotech-3bcb0aaf97164e33Pharma Surgeen2026-07-25T11:08:39.000ZWhy is Cathie Wood Shifting from Tech to Biotechhttps://www.pharmaradar360.com/article/millions-could-access-cheaper-monthly-hiv-pill-under-new-merck-licensing-deal-17d9791f83d0f3ddPharma Surgeen2026-07-25T11:03:41.000ZMillions could access cheaper monthly HIV pill under new Merck licensing dealhttps://www.pharmaradar360.com/article/sls-stock-kicks-off-week-in-green-ceo-flags-role-in-eu-biotech-policy-talks-that-85917f0651d26f85Pharma Surgeen2026-07-25T10:54:30.000ZSLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvalshttps://www.pharmaradar360.com/article/does-teva-pharmaceutical-industries-nyse-teva-still-look-undervalued-after-a-260-c6e96463ffd05ae4Pharma Surgeen2026-07-25T10:39:41.000ZDoes Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run?https://www.pharmaradar360.com/article/does-teva-pharmaceutical-industries-nyse-teva-still-look-undervalued-after-a-260-71320e958e9cb0eePharma Surgeen2026-07-25T10:39:40.000ZDoes Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run?https://www.pharmaradar360.com/article/fugitive-doctor-on-run-for-21-years-was-living-as-an-l-a-biotech-executive-43bea266d1a82f2aPharma Surgeen2026-07-25T10:14:53.000ZFugitive doctor on run for 21 years was living as an L.A. biotech executivehttps://www.pharmaradar360.com/article/185750-forecast-price-target-prediction-for-2027-861d61497e8c8664Pharma Surgeen2026-07-25T10:11:44.000Z185750 Forecast — Price Target — Prediction for 2027https://www.pharmaradar360.com/article/takeda-pharmaceutical-co-ltd-0rn3-q3-2025-earnings-report-results-call-slides-0a71a7cc12b0b7d4Pharma Surgeen2026-07-25T10:09:39.000ZTakeda Pharmaceutical Co Ltd (0RN3) Q3 2025 Earnings Report - Results, Call & Slideshttps://www.pharmaradar360.com/article/a-daily-fiber-supplement-reduced-knee-arthritis-pain-and-improved-strength-7428d902f74853b9Pharma Surgeen2026-07-25T10:01:05.000ZA daily fiber supplement reduced knee arthritis pain and improved strengthhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-moleculin-biotech-inc-nasdaq-mbrx-6b46ae252e838a5bPharma Surgeen2026-07-25T09:56:02.000ZEnterprise value to EBIT forward of Moleculin Biotech, Inc. – NASDAQ:MBRXhttps://www.pharmaradar360.com/article/fubara-s-medical-industrial-revolution-rivers-rises-as-africa-s-next-pharmaceuti-40dc6bd8aedf8197Pharma Surgeen2026-07-25T09:34:11.000ZFubara’s Medical Industrial Revolution: Rivers rises as Africa’s next pharmaceutical hubhttps://www.pharmaradar360.com/article/us-listed-rare-disease-biotech-hit-with-full-clinical-hold-data-unblinding-ahead-420e6b8917890de5Pharma Surgeen2026-07-25T09:33:25.000ZUS-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Aheadhttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-nasdaq-bmrn-presents-a-high-quality-breakout-setup-with-485b81b6467a0cd3Pharma Surgeen2026-07-25T09:30:52.000ZBioMarin Pharmaceutical (NASDAQ:BMRN) Presents a High-Quality Breakout Setup with Strong Technical Ratingshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-wst-shares-sold-by-kbc-group-nv-0792231d4a086ec1Pharma Surgeen2026-07-25T09:17:44.000ZWest Pharmaceutical Services, Inc. $WST Shares Sold by KBC Group NVhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-07-25T08:27:42.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/epoch-investment-partners-inc-acquires-39-745-shares-of-west-pharmaceutical-serv-8ebbaa0d4b163f04Pharma Surgeen2026-07-25T08:26:45.000ZEpoch Investment Partners Inc. Acquires 39,745 Shares of West Pharmaceutical Services, Inc. $WSThttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-inc-wst-a-bargain-after-7-7-d-2b3c898e4e24ba43Pharma Surgeen2026-07-25T08:26:15.000ZIs West Pharmaceutical Services Inc (WST) a Bargain After 7.7% Dhttps://www.pharmaradar360.com/article/kintor-pharmaceutical-ltd-revenue-breakdown-hkex-9939-a66572cf0d4d6649Pharma Surgeen2026-07-25T08:17:57.000ZKintor Pharmaceutical Ltd Revenue Breakdown – HKEX:9939https://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-wst-q1-2026-earnings-report-results-call-slides-ead0e9b082437a70Pharma Surgeen2026-07-25T07:48:32.000ZWest Pharmaceutical Services, Inc. (WST) Q1 2026 Earnings Report - Results, Call & Slideshttps://www.pharmaradar360.com/article/sommarenkat-jenny-nilsson-skadespelare-strosa-i-charmiga-gamla-stan-bc1b2f8429766ba7Pharma Surgeen2026-07-25T07:23:47.000ZSommarenkät: Jenny Nilsson, skådespelare – Strosa i charmiga gamla stanhttps://www.pharmaradar360.com/article/video-254-exciting-news-apitegromab-phase-3-trial-updates-bob-dnmst6vtzo-e0c0c8abbf51a793Pharma Surgeen2026-07-25T07:02:20.000ZVideo #254 - EXCITING NEWS - Apitegromab Phase 3 Trial Updates Bob (dNmSt6vtZo)https://www.pharmaradar360.com/article/cabio-biotech-wuhan-co-ltd-class-a-revenue-breakdown-sse-688089-f3091d9ed203ece4Pharma Surgeen2026-07-25T06:53:03.000ZCABIO Biotech (Wuhan) Co. Ltd. Class A Revenue Breakdown – SSE:688089https://www.pharmaradar360.com/article/chongqing-lummy-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-300006-641c1afd34535d5dPharma Surgeen2026-07-25T06:46:28.000ZChongqing Lummy Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SZSE:300006https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-cardiac-biotech-solutions-inc-otc-cbsc-b2a828ab53737672Pharma Surgeen2026-07-25T06:41:20.000ZEnterprise value to EBIT forward of Cardiac Biotech Solutions Inc. – OTC:CBSChttps://www.pharmaradar360.com/article/greek-hospital-drug-funding-crisis-pharma-sector-warns-on-patient-access-6a15773e0daa8251Pharma Surgeen2026-07-25T06:34:11.000ZGreek hospital drug funding crisis, pharma sector warns on patient accesshttps://www.pharmaradar360.com/article/draper-to-set-up-venture-capital-firm-in-busan-to-invest-in-k-content-physical-a-a116ed7357064792Pharma Surgeen2026-07-25T05:31:00.000ZDraper to Set Up Venture Capital Firm in Busan to Invest in K-Content, Physical AI, Biotech and Blockchainhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-us-will-release-its-earnings-report-on-july-30-fb8a2164d1d70016Pharma Surgeen2026-07-25T05:13:03.000ZTakeda Pharmaceutical (TAK.US) will release its earnings report on July 30.https://www.pharmaradar360.com/article/fda-panel-gives-nod-to-six-controversial-peptides-f02d20943de4c6aaPharma Surgeen2026-07-25T04:33:14.000ZFDA panel gives nod to six controversial peptideshttps://www.pharmaradar360.com/article/samjin-pharmaceutical-co-ltd-revenue-breakdown-krx-005500-dd62c7080ca42147Pharma Surgeen2026-07-25T04:31:15.000ZSamjin Pharmaceutical Co., Ltd. Revenue Breakdown – KRX:005500https://www.pharmaradar360.com/article/u-s-ipo-weekly-recap-crispr-biotech-pops-44-as-more-names-join-the-ipo-pipeline-98c60f17476a8d94Pharma Surgeen2026-07-25T04:30:00.000ZU.S. IPO Weekly Recap: CRISPR Biotech Pops 44% As More Names Join The IPO Pipelinehttps://www.pharmaradar360.com/article/bicara-s-cancer-drug-enters-crucial-trial-phase-says-ceo-claire-mazumdar-504e20a964248910Pharma Surgeen2026-07-25T03:41:54.000ZBicara’s cancer drug enters crucial trial phase, says CEO Claire Mazumdarhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-biotech-growth-trust-plc-turquoise-biogl-28a9cbf07c1bf563Pharma Surgeen2026-07-25T03:39:41.000ZEnterprise value to revenue forward of Biotech Growth Trust PLC – TURQUOISE:BIOGLhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-stock-sees-margin-improvement-narrative-backed-e52ce20734007004Pharma Surgeen2026-07-25T03:38:58.000ZWest Pharmaceutical Services (WST) Stock Sees Margin Improvement Narrative Backed By Q2 2026 Resultshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-stock-sees-margin-improvement-narrative-backed-b56c0ea206934abePharma Surgeen2026-07-25T03:38:57.000ZWest Pharmaceutical Services (WST) Stock Sees Margin Improvement Narrative Backed By Q2 2026 Resultshttps://www.pharmaradar360.com/article/chugai-pharmaceutical-chgcf-reports-strong-first-half-earnings-a95d97db44dffa89Pharma Surgeen2026-07-25T03:33:45.000ZChugai Pharmaceutical (CHGCF) Reports Strong First Half Earningshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-co-ltd-revenue-breakdown-otc-tkphf-5b1e3032af4af548Pharma Surgeen2026-07-25T03:32:58.000ZTakeda Pharmaceutical Co., Ltd. Revenue Breakdown – OTC:TKPHFhttps://www.pharmaradar360.com/article/krystal-biotech-inc-revenue-breakdown-nasdaq-krys-b656b361399351c4Pharma Surgeen2026-07-25T03:23:23.000ZKrystal Biotech, Inc. Revenue Breakdown – NASDAQ:KRYShttps://www.pharmaradar360.com/article/jiangxi-synergy-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-300636-61e51cf9a5e886f8Pharma Surgeen2026-07-25T03:11:26.000ZJiangxi Synergy Pharmaceutical Co. Ltd. Class A Revenue Breakdown – SZSE:300636https://www.pharmaradar360.com/article/gene-editing-biotech-scribe-jumps-44-in-market-debut-targets-heart-disease-1b24b3e8635ebe30Pharma Surgeen2026-07-25T02:45:00.000ZGene-Editing Biotech Scribe Jumps 44% in Market Debut, Targets Heart Diseasehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-medicofarma-biotech-spolka-akcyjna-newconnec-c69dc2d0742c246bPharma Surgeen2026-07-25T02:09:54.000ZEnterprise value to EBIT forward of Medicofarma Biotech Spolka Akcyjna – NEWCONNECT:MDBhttps://www.pharmaradar360.com/article/beijing-beilu-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-300016-a1c23937b621a7b7Pharma Surgeen2026-07-25T02:07:46.000ZBeijing Beilu Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SZSE:300016https://www.pharmaradar360.com/article/veraxa-biotech-ag-nasdaq-vrxa-appoints-christoph-erkel-as-chief-scientific-offic-a810c5e9b7181078Pharma Surgeen2026-07-25T02:04:00.000ZVERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officerhttps://www.pharmaradar360.com/article/this-week-in-boomtown-aviation-industry-in-ohio-affordable-housing-future-of-bio-51d5297eeb42b45bPharma Surgeen2026-07-25T01:39:00.000ZThis Week in Boomtown: Aviation industry in Ohio; affordable housing; future of biotechhttps://www.pharmaradar360.com/article/proprietary-biobotanical-microemulsion-technologies-c3b98d4fa2412c22Pharma Surgeen2026-07-25T01:33:50.000ZProprietary Biobotanical Microemulsion Technologieshttps://www.pharmaradar360.com/article/a215380-static-price-chart-kolmar-biotech-inc-kr7215380007-71c724dfe5eec533Pharma Surgeen2026-07-25T01:11:43.000ZA215380: Static price chart | Kolmar BioTech, Inc. | KR7215380007https://www.pharmaradar360.com/article/kolmar-biotech-inc-shareholders-board-members-managers-and-company-profile-kr721-a5992804a39b6a4aPharma Surgeen2026-07-25T01:11:43.000ZKolmar BioTech, Inc.: Shareholders Board Members Managers and Company Profile | KR7215380007https://www.pharmaradar360.com/article/west-pharmaceutical-services-i-wst-stock-forecasts-8708d5e13e78258bPharma Surgeen2026-07-25T00:53:12.000ZWest Pharmaceutical Services, I (WST) Stock Forecastshttps://www.pharmaradar360.com/article/stifel-reiterates-mirum-pharmaceuticals-stock-rating-after-rival-trial-fails-81e24ae1bdfed904Pharma Surgeen2026-07-25T00:16:21.000ZStifel reiterates Mirum Pharmaceuticals stock rating after rival trial failshttps://www.pharmaradar360.com/article/catering-417dea081ecb4e00Pharma Surgeen2026-07-25T00:00:00.000Zcateringhttps://www.pharmaradar360.com/article/spatiotemporal-multi-omics-reveals-lineage-spatial-and-functional-heterogeneity-e84924ea04f571e9Pharma Surgeen2026-07-25T00:00:00.000ZSpatiotemporal multi-omics reveals lineage, spatial and functional heterogeneity of tumor-associated macrophages and therapeutic vulnerabilities in the tumor microenvironmenthttps://www.pharmaradar360.com/article/comparison-of-whole-genome-sequencing-with-clinical-targeted-panel-sequencing-of-cc282f8d705f195bPharma Surgeen2026-07-25T00:00:00.000ZComparison of whole genome sequencing with clinical targeted panel sequencing of metastatic prostate cancer: insights from real-world datahttps://www.pharmaradar360.com/article/prediction-of-single-cell-expression-from-low-plex-immunofluorescence-images-for-8c32e0fa2a82bb6ePharma Surgeen2026-07-25T00:00:00.000ZPrediction of single cell expression from low-plex immunofluorescence images for guiding precision oncologyhttps://www.pharmaradar360.com/article/understanding-public-perspectives-on-direct-to-consumer-pharmacogenomic-testing-7f4d2f18346bbc6fPharma Surgeen2026-07-25T00:00:00.000ZUnderstanding public perspectives on direct-to-consumer pharmacogenomic testing in the UK: a qualitative studyhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-d44e1196fcde3687Pharma Surgeen2026-07-25T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-38278a26ee1f3551Pharma Surgeen2026-07-25T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-6482b13a4d1370c5Pharma Surgeen2026-07-25T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-01ca72eced5bef72Pharma Surgeen2026-07-25T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-a4e67c6176a3de4dPharma Surgeen2026-07-25T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-faf3c0c18f0c1213Pharma Surgeen2026-07-25T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-2e74240a2a8dd266Pharma Surgeen2026-07-25T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-c46025040ac0e5c8Pharma Surgeen2026-07-25T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-c8baab94b67bd9cdPharma Surgeen2026-07-25T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-e8526dc0c79a844fPharma Surgeen2026-07-25T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-d3cc318cea1059b4Pharma Surgeen2026-07-25T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-a177f1e05c6960bdPharma Surgeen2026-07-25T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-b61213986f329bfbPharma Surgeen2026-07-25T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-6feb50b7023d9605Pharma Surgeen2026-07-25T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/25-69-27f176915ad196dePharma Surgeen2026-07-25T00:00:00.000Z25 ก.ค. 69อย. กำชับผู้ประกอบการใช้วัตถุเจือปนอาหารที่มีไนไตรท์ให้ถูกต้อง ตรวจเข้มสถานที่ผลิตอาหารกลุ่มเสี่ยง พร้อมเผยแพร่สื่อแนะนำการใช้อ่านเพิ่มเติม →https://www.pharmaradar360.com/article/full-blood-count-platelet-parameters-in-sickle-cell-disease-a-systematic-review-051bc648df07158dPharma Surgeen2026-07-25T00:00:00.000ZFull Blood Count Platelet Parameters in Sickle Cell Disease: A Systematic Review of Thrombocytosis, Thrombocytopenia, and Clinical Implicationshttps://www.pharmaradar360.com/article/quality-of-inpatient-clinical-documentation-a-bed-head-ticket-audit-at-a-tertiar-409bfbd535aae580Pharma Surgeen2026-07-25T00:00:00.000ZQuality of Inpatient Clinical Documentation: A Bed Head Ticket Audit at a Tertiary Care Hospital in Sri Lankahttps://www.pharmaradar360.com/article/clinical-drivers-of-cesarean-sections-during-the-covid-19-pandemic-a-robson-clas-f9e03364fa31dd6bPharma Surgeen2026-07-25T00:00:00.000ZClinical Drivers of Cesarean Sections During the COVID-19 Pandemic: A Robson Classification-Based Multivariable Analysishttps://www.pharmaradar360.com/article/platelet-concentrates-in-periodontal-regeneration-a-review-of-current-evidence-a-d357326aa0fbda83Pharma Surgeen2026-07-25T00:00:00.000ZPlatelet Concentrates in Periodontal Regeneration: A Review of Current Evidence and Clinical Perspectiveshttps://www.pharmaradar360.com/article/lt-b-gt-artificial-intelligence-in-admet-prediction-transforming-drug-safety-and-b4365db89883d392Pharma Surgeen2026-07-25T00:00:00.000Z&lt;b&gt;Artificial Intelligence in ADMET Prediction: Transforming Drug Safety and Pharmacokinetic Assessment &lt;/b&gt;https://www.pharmaradar360.com/article/virtual-reality-based-rehabilitation-versus-conventional-physiotherapy-for-impro-7352e2d99c19f50dPharma Surgeen2026-07-25T00:00:00.000ZVirtual Reality-Based Rehabilitation versus Conventional Physiotherapy for Improving Balance, Functional Mobility, and Fall Risk in Parkinson's Disease: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/development-and-evaluation-of-polyherbal-antiinflammantory-gel-using-azadirachta-7d72bf3040a97bdbPharma Surgeen2026-07-25T00:00:00.000ZDEVELOPMENT AND EVALUATION OF POLYHERBAL ANTIINFLAMMANTORY GEL USING AZADIRACHTA INDICA ANDTARAXACUM OFFICINALEhttps://www.pharmaradar360.com/article/adaptive-communication-strategies-for-drug-prevention-a-netnographic-analysis-of-1be82c489f9e08e8Pharma Surgeen2026-07-25T00:00:00.000ZAdaptive Communication Strategies for Drug Prevention: A Netnographic Analysis of the Surabaya BNN’s Instagram Accounthttps://www.pharmaradar360.com/article/optimizing-hemostasis-in-hysteroscopic-myomectomy-a-randomized-clinical-trial-of-8bd4f66d18151877Pharma Surgeen2026-07-25T00:00:00.000ZOptimizing Hemostasis in Hysteroscopic Myomectomy: A Randomized Clinical Trial of Vaginal Danazol Versus Diphereline in Women With Abnormal Uterine Bleedinghttps://www.pharmaradar360.com/article/balancing-capacities-in-positive-and-transcultural-psychotherapy-a-case-informed-72a75198dbf879dePharma Surgeen2026-07-25T00:00:00.000ZBalancing capacities in Positive and Transcultural Psychotherapy: A case-informed reflection from clinical practicehttps://www.pharmaradar360.com/article/transformations-of-anger-an-integrative-model-for-clinical-work-with-greed-envy-0eaf66544f66cb50Pharma Surgeen2026-07-25T00:00:00.000ZTransformations of anger: An integrative model for clinical work with greed, envy, jealousy, and guilthttps://www.pharmaradar360.com/article/peer-review-report-for-assessing-perception-and-motivation-of-medical-student-co-a50d1fd6a115787aPharma Surgeen2026-07-25T00:00:00.000ZPeer Review Report For: Assessing perception and motivation of medical student concerning clinical learning in the Faculty of Medicine of Sousse (Tunisia) [version 2; peer review: 2 approved with reservations]https://www.pharmaradar360.com/article/role-of-textiles-in-medical-clinical-case-reports-81ff857413019520Pharma Surgeen2026-07-25T00:00:00.000ZRole of Textiles in Medical Clinical Case Reportshttps://www.pharmaradar360.com/article/elmas-s-theory-of-medical-thermodynamics-and-the-fifth-law-of-thermodynamics-bas-60d428b528f369eaPharma Surgeen2026-07-25T00:00:00.000ZELMAS’s Theory of Medical Thermodynamics and the Fifth Law of Thermodynamics Based Closed-Loop Feedback Bio-Robotic Resonance Method and FM Modulated Smart Drug Algorithm in Glioblastoma - Brain Cancer Treatmenthttps://www.pharmaradar360.com/article/recent-advances-in-cancer-treatment-drugs-the-developmental-journey-from-preclin-f20777a62d1ef516Pharma Surgeen2026-07-25T00:00:00.000ZRecent Advances in Cancer Treatment Drugs: The Developmental Journey from Preclinical Discovery to Market Approvalhttps://www.pharmaradar360.com/article/clinical-outcomes-and-quality-of-life-after-laparoscopic-nissen-fundoplication-f-856de3bf5fbc554bPharma Surgeen2026-07-25T00:00:00.000ZClinical Outcomes and Quality of Life after Laparoscopic Nissen Fundoplication for Refractory Gastroesophageal Reflux Disease: A Prospective Cohort Study from Vietnamhttps://www.pharmaradar360.com/article/hemorrhagic-hepatic-cysts-mimicking-mucinous-cystic-neoplasm-imaging-features-an-e01701af1c83bc18Pharma Surgeen2026-07-25T00:00:00.000ZHemorrhagic Hepatic Cysts Mimicking Mucinous Cystic Neoplasm: Imaging Features and Clinical Implicationshttps://www.pharmaradar360.com/article/recent-trends-in-biomarker-based-early-detection-of-hepatic-disorders-in-clinica-cc19b518f8e2fa03Pharma Surgeen2026-07-25T00:00:00.000ZRecent Trends in Biomarker-Based Early Detection of Hepatic Disorders in Clinical Biochemistryhttps://www.pharmaradar360.com/article/persuasion-in-scientific-journal-articles-exploring-persuasiveness-and-informati-db2370c2ed4a4036Pharma Surgeen2026-07-25T00:00:00.000ZPersuasion in Scientific Journal Articles: Exploring Persuasiveness and Informativeness among Authors and Readershttps://www.pharmaradar360.com/article/associations-between-inflammatory-markers-and-myocardial-injury-in-patients-trea-25f4a357406481c5Pharma Surgeen2026-07-25T00:00:00.000ZAssociations between inflammatory markers and myocardial injury in patients treated with pitavastatin: A retrospective clinical studyhttps://www.pharmaradar360.com/article/xiaoshen-formula-delays-progression-of-diabetic-kidney-disease-and-improves-gluc-62b64e2f7603cc31Pharma Surgeen2026-07-25T00:00:00.000ZXiaoshen formula delays progression of diabetic kidney disease and improves glucose and lipid metabolism: Association with the JAK/STAT pathwayhttps://www.pharmaradar360.com/article/molecular-mechanism-of-ephedrine-regulated-ferroptosis-in-asthma-via-pkm2-acsl4-40d24cfb9778f3cbPharma Surgeen2026-07-25T00:00:00.000ZMolecular mechanism of ephedrine-regulated ferroptosis in asthma via PKM2–ACSL4 lactylationhttps://www.pharmaradar360.com/article/the-influence-of-linc00511-and-mdm2-mdm4-in-lung-carcinoma-implications-for-immu-43b6edc6360053a2Pharma Surgeen2026-07-25T00:00:00.000ZThe influence of LINC00511 and MDM2/MDM4 in lung carcinoma: Implications for immunological therapeutic strategieshttps://www.pharmaradar360.com/article/clinical-applicability-of-whisper-based-automatic-transcription-for-korean-speec-fae4b6d4d324c4c9Pharma Surgeen2026-07-25T00:00:00.000ZClinical Applicability of Whisper-Based Automatic Transcription for Korean Speech Audiometry Sentence Tests in Older Adults with Hearing Losshttps://www.pharmaradar360.com/article/clinical-significance-of-apoptosis-marker-caspase-3-tumor-marker-cea-and-electro-72920b44aa7c65acPharma Surgeen2026-07-25T00:00:00.000ZClinical Significance of Apoptosis Marker Caspase-3, Tumor Marker CEA, and Electrolyte Imbalance in Breast Cancer Patientshttps://www.pharmaradar360.com/article/real-world-experience-using-the-clinical-treatment-score-at-5-years-cts5-and-bre-6655d40c6c828297Pharma Surgeen2026-07-25T00:00:00.000ZReal-World Experience Using the Clinical Treatment Score at 5 Years (CTS5) and Breast Cancer Index (BCI) to Guide Extended Adjuvant Endocrine Therapyhttps://www.pharmaradar360.com/article/a-preliminary-study-on-the-efficacy-and-safety-of-a-novel-digital-therapeutic-de-6069a228481e368cPharma Surgeen2026-07-25T00:00:00.000ZA Preliminary Study on the Efficacy and Safety of a Novel Digital Therapeutic Device: A Randomized Clinical Trial in South Korean Pediatric Patients With Attention-Deficit/Hyperactivity Disorderhttps://www.pharmaradar360.com/article/effect-of-oral-antioxidant-supplementation-containing-resveratrol-grape-seed-ext-2fccc905fb89a8c0Pharma Surgeen2026-07-25T00:00:00.000ZEffect of oral antioxidant supplementation containing resveratrol, grape seed extract, L-carnosine, and <i>Curcuma longa</i> on clinical signs of skin aging: A prospective pilot studyhttps://www.pharmaradar360.com/article/effects-of-blue-green-space-exposure-on-psychological-well-being-and-mental-heal-bfb659e1505c9c08Pharma Surgeen2026-07-25T00:00:00.000ZEffects Of Blue-Green Space Exposure On Psychological Well-Being And Mental Health: A Rapid Reviewhttps://www.pharmaradar360.com/article/comparative-analysis-of-weighted-bayesian-belief-network-and-fuzzy-weighted-baye-98d80b7184d26359Pharma Surgeen2026-07-25T00:00:00.000ZComparative Analysis of Weighted Bayesian Belief Network and Fuzzy Weighted Bayesian Belief Network in Clinical Decision Supporthttps://www.pharmaradar360.com/article/impact-of-dual-task-training-vs-single-task-training-on-balance-gait-speed-and-c-49b407a35c00ba96Pharma Surgeen2026-07-25T00:00:00.000ZImpact of Dual task training vs single task training on balance, gait speed and cognitive function in Post stroke patients: A systematic reviewhttps://www.pharmaradar360.com/article/integrative-forensic-modalities-in-disaster-victim-identification-a-comparative-ad1475fd3eb27033Pharma Surgeen2026-07-25T00:00:00.000ZIntegrative Forensic Modalities in Disaster Victim Identification: A Comparative Analytical Study of DNA Profiling, Forensic Odontology, and Digital Forensics in Mass Fatality Incidentshttps://www.pharmaradar360.com/article/therapeutic-efficacy-of-ajmodadi-churna-and-kati-basti-with-kottamchukadi-taila-4b9fd5d993a56b19Pharma Surgeen2026-07-25T00:00:00.000ZTherapeutic Efficacy Of Ajmodadi Churna And Kati Basti With Kottamchukadi Taila In The Management Of Gridhrasi (Sciatica): A Randomized Comparative Clinical Studyhttps://www.pharmaradar360.com/article/predictors-of-dynamic-balance-and-functional-mobility-in-community-dwelling-olde-a94aaca097675127Pharma Surgeen2026-07-25T00:00:00.000ZPredictors of Dynamic Balance and Functional Mobility in Community-Dwelling Older Adults: The Relative Contributions of Multi-Joint Lower-Extremity Muscle Strengthhttps://www.pharmaradar360.com/article/artificial-intelligence-in-osteoarthritis-pain-management-current-applications-a-101194b703cdfeefPharma Surgeen2026-07-25T00:00:00.000ZArtificial Intelligence in Osteoarthritis Pain Management: Current Applications and Future Perspectiveshttps://www.pharmaradar360.com/article/assessment-of-corneal-endothelial-changes-in-patients-with-pseudoexfoliation-syn-60b2bca2b7f27c97Pharma Surgeen2026-07-25T00:00:00.000ZAssessment Of Corneal Endothelial Changes In Patients With Pseudoexfoliation Syndrome Using Non Contact Specular Microscopyhttps://www.pharmaradar360.com/article/predictive-value-of-spermatic-vein-diameter-threshold-and-clinical-factors-for-s-078636b8789de8a9Pharma Surgeen2026-07-25T00:00:00.000ZPredictive Value of Spermatic Vein Diameter Threshold and Clinical Factors for Semen Quality Improvement after Varicocelectomy in Rural Men Aged 30–35 Years: A Prospective Observational Studyhttps://www.pharmaradar360.com/article/formulation-and-evaluation-of-herbal-gel-da798585761e2684Pharma Surgeen2026-07-25T00:00:00.000ZFORMULATION AND EVALUATION OF HERBAL GELhttps://www.pharmaradar360.com/article/enhancing-quality-management-systems-qms-in-clinical-data-management-using-machi-52720f0747ea08f6Pharma Surgeen2026-07-25T00:00:00.000ZEnhancing Quality Management Systems (QMS) in Clinical Data Management using Machine Learning: A Systematic Scoping Review and Proposed Reference Frameworkhttps://www.pharmaradar360.com/article/phytochemical-profiling-quantitative-estimation-isolation-and-characterization-o-7b7148c289fbc53dPharma Surgeen2026-07-25T00:00:00.000ZPHYTOCHEMICAL PROFILING, QUANTITATIVE ESTIMATION, ISOLATION AND CHARACTERIZATION OF BIOACTIVE CONSTITUENTS FROM JUSTICIA BETONICA (L.) AND VIGNA TRILOBATA (L.) VERDC.https://www.pharmaradar360.com/article/development-and-validation-of-a-high-performance-liquid-chromatographic-hplc-met-4c8286c129cdb0fdPharma Surgeen2026-07-25T00:00:00.000ZDevelopment and Validation of a High-Performance Liquid Chromatographic (HPLC) Method for the Simultaneous Estimation of Five Related Pyridine Compounds Using a Mixed-Mode Primesep 100 Column.https://www.pharmaradar360.com/article/gender-and-operative-difficulty-in-laparoscopic-cholecystectomy-2d1a14dc09628404Pharma Surgeen2026-07-25T00:00:00.000ZGENDER AND OPERATIVE DIFFICULTY IN LAPAROSCOPIC CHOLECYSTECTOMYhttps://www.pharmaradar360.com/article/comparative-evaluation-of-external-apical-root-resorption-following-en-masse-ret-d6c81cf132d7e2dePharma Surgeen2026-07-25T00:00:00.000ZComparative Evaluation of External Apical Root Resorption Following En-Masse Retraction Using Conventional Anchorage and Temporary Anchorage Devices: A CBCT Studyhttps://www.pharmaradar360.com/article/clinical-outcomes-and-recurrence-prevention-in-laparoscopic-wells-rectopexy-for-915aa2b64330c2c4Pharma Surgeen2026-07-25T00:00:00.000ZClinical Outcomes and Recurrence Prevention in Laparoscopic Wells Rectopexy for Rectal Prolapse through Mesh Trimming and Fixation Techniqueshttps://www.pharmaradar360.com/article/clinical-significance-of-lymph-node-count-in-colon-cancer-surgery-a-tumour-locat-591deaea176795c3Pharma Surgeen2026-07-25T00:00:00.000ZClinical Significance of Lymph Node Count in Colon Cancer Surgery: A Tumour Location-stratified Prognostic Analysis Based on an Integrated Phase-III Randomized Controlled Trial (JCOG2310AS3)https://www.pharmaradar360.com/article/prediction-of-pathological-complete-response-after-chemoradiation-for-locally-ad-e0ed343f85d7fb76Pharma Surgeen2026-07-25T00:00:00.000ZPrediction of Pathological Complete Response after Chemoradiation for Locally Advanced Rectal Cancer Using Machine Learning with Clinical Features, the INTERCEPTOR Study Preliminary Modelhttps://www.pharmaradar360.com/article/predominance-of-m1uk-type-strains-and-their-clinical-impact-in-invasive-streptoc-fb7c02f993abca88Pharma Surgeen2026-07-25T00:00:00.000ZPredominance of M1UK type strains and their clinical impact in invasive Streptococcus pyogenes infections in Japan, 2023–2025https://www.pharmaradar360.com/article/development-and-internal-validation-of-a-clinical-prediction-model-for-dual-anti-e35f9b613737a068Pharma Surgeen2026-07-25T00:00:00.000ZDevelopment and Internal Validation of a Clinical Prediction Model for Dual Antiplatelet Therapy Efficacy in Acute Ischemic Stroke: A Machine Learning Approachhttps://www.pharmaradar360.com/article/visualizing-the-future-impact-of-holographic-visualization-on-teaching-minimally-49744b0912ce8081Pharma Surgeen2026-07-25T00:00:00.000ZVisualizing the Future: Impact of Holographic Visualization on Teaching Minimally Invasive Veneer Preparation: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-functional-and-radiological-profile-of-fibrotic-interstitial-lung-disea-b796ba326bbc91a8Pharma Surgeen2026-07-25T00:00:00.000ZClinical, functional, and radiological profile of fibrotic interstitial lung disease at high altitude: a registry-based cohort from two referral centres in Bogotá, Colombia (2,600 metres above sea level)https://www.pharmaradar360.com/article/platelet-concentrates-in-implant-dentistry-biological-basis-clinical-application-05bbe214d8c87a84Pharma Surgeen2026-07-25T00:00:00.000ZPlatelet concentrates in implant dentistry: Biological basis, clinical applications, and future perspectiveshttps://www.pharmaradar360.com/article/clinical-and-radiographic-outcomes-after-surgical-treatment-of-supination-adduct-5961501abcbbf7c5Pharma Surgeen2026-07-25T00:00:00.000ZClinical and radiographic outcomes after surgical treatment of supination-adduction type ankle fractures in older (≥65 years) and younger (&lt;65 years) patients: a retrospective single-center comparative study in Koreahttps://www.pharmaradar360.com/article/absolute-lt-sup-gt-19-lt-sup-gt-f-qnmr-quantification-of-fluorinated-pharmaceuti-5f0dde94c06553f9Pharma Surgeen2026-07-25T00:00:00.000ZAbsolute &lt;sup&gt;19&lt;/sup&gt;F-qNMR Quantification of Fluorinated Pharmaceuticals: Fluorometholone, Flurbiprofen, and Flutamidehttps://www.pharmaradar360.com/article/aso-visual-abstract-hepatectomy-plus-chemotherapy-or-chemotherapy-alone-for-rese-747e1b345e24b697Pharma Surgeen2026-07-25T00:00:00.000ZASO Visual Abstract: Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trialhttps://www.pharmaradar360.com/article/leveraging-fourier-transform-infrared-spectroscopy-for-community-drug-checking-t-9760e033e9fa17e7Pharma Surgeen2026-07-25T00:00:00.000ZLeveraging fourier-transform infrared spectroscopy for community drug checking to bridge clinical care and harm reduction services: case reporthttps://www.pharmaradar360.com/article/risk-prediction-models-for-venous-thromboembolism-in-the-intensive-care-unit-a-s-2341ba8b1510d69aPharma Surgeen2026-07-25T00:00:00.000ZRisk prediction models for venous thromboembolism in the intensive care unit: a systematic review protocol assessing model performance, risk of bias, and clinical applicabilityhttps://www.pharmaradar360.com/article/preoperative-antibiotics-for-mild-or-moderate-acute-cholecystitis-pommac-study-p-c7a3ad0b1db8306fPharma Surgeen2026-07-25T00:00:00.000ZPreoperative antibiotics for mild or moderate acute cholecystitis (POMMAC): study protocol for a non-inferiority, open-label, randomized controlled trialhttps://www.pharmaradar360.com/article/randomised-placebo-controlled-study-to-assess-the-safety-and-efficacy-of-enteros-6e1649692906a188Pharma Surgeen2026-07-25T00:00:00.000ZRandomised, placebo-controlled study to assess the safety and efficacy of Enterosgel® in the treatment of functional abdominal pain in children and young people (ENTOPIC): study protocol for a clinical trialhttps://www.pharmaradar360.com/article/acute-pulmonary-embolism-clinical-and-echocardiographic-recognition-of-normotens-e490e347f886184dPharma Surgeen2026-07-25T00:00:00.000ZAcute pulmonary embolism: clinical and echocardiographic recognition of normotensive shockhttps://www.pharmaradar360.com/article/tailored-fc-r-blockade-enhances-immune-checkpoint-therapy-and-overcomes-resistan-17769ef5f6f7e2a3Pharma Surgeen2026-07-25T00:00:00.000ZTailored FcγR blockade enhances immune checkpoint therapy and overcomes resistancehttps://www.pharmaradar360.com/article/elevated-homocysteine-and-non-suicidal-self-injury-in-adolescent-depression-poss-76e67b406fcfb016Pharma Surgeen2026-07-25T00:00:00.000ZElevated homocysteine and non-suicidal self-injury in adolescent depression: possible sex-specific clinical associationshttps://www.pharmaradar360.com/article/ischemic-stroke-molecular-mechanisms-of-blood-brain-barrier-dysfunction-and-oppo-90020bc2ae30ed15Pharma Surgeen2026-07-25T00:00:00.000ZIschemic stroke: molecular mechanisms of blood-brain barrier dysfunction and opportunities for drug developmenthttps://www.pharmaradar360.com/article/malaria-diagnosis-practices-in-formal-private-drug-retail-shops-in-the-ho-munici-8ad91c9c36bc8829Pharma Surgeen2026-07-25T00:00:00.000ZMalaria diagnosis practices in formal private drug retail shops in the Ho Municipality, Ghana: a cross-sectional surveyhttps://www.pharmaradar360.com/article/comparison-of-chatgpt-gemini-and-deepseek-responses-to-questions-on-medication-r-b9b236cf6a55dae9Pharma Surgeen2026-07-25T00:00:00.000ZComparison of ChatGPT, Gemini, and DeepSeek responses to questions on medication-related osteonecrosis of the jaw (MRONJ): a comparative analysis of expert-rated clinical quality, readability, response time, and clinical safety riskhttps://www.pharmaradar360.com/article/construction-of-a-clinical-model-for-proximal-caries-via-machine-learning-algori-e4904909d7711207Pharma Surgeen2026-07-25T00:00:00.000ZConstruction of a clinical model for proximal caries via machine learning algorithmshttps://www.pharmaradar360.com/article/effectiveness-of-three-remote-tele-prehabilitation-strategies-in-patients-awaiti-61c5d658afc562fbPharma Surgeen2026-07-25T00:00:00.000ZEffectiveness of three remote tele-prehabilitation strategies in patients awaiting lower limb arthroplasty: a three-arm randomized controlled trialhttps://www.pharmaradar360.com/article/antibiotic-dispensing-practices-and-patterns-of-non-prescription-antibiotic-sale-fe3362e8968f40e8Pharma Surgeen2026-07-25T00:00:00.000ZAntibiotic dispensing practices and patterns of non-prescription antibiotic sales among retail drug outlets in Ghanahttps://www.pharmaradar360.com/article/clinical-features-and-imaging-diagnostic-challenges-of-fetus-in-fetu-associated-cdc897326183728bPharma Surgeen2026-07-25T00:00:00.000ZClinical features and imaging diagnostic challenges of fetus-in-fetu associated with abdominal cryptorchidism: a case reporthttps://www.pharmaradar360.com/article/very-early-onset-inflammatory-bowel-disease-in-jordan-a-single-center-case-serie-62ef6f90126d0e47Pharma Surgeen2026-07-25T00:00:00.000ZVery early onset inflammatory bowel disease in Jordan: a single-center case series of clinical, genetic, and therapeutic featureshttps://www.pharmaradar360.com/article/implementation-strategies-used-in-clinical-practice-guidelines-in-older-adults-m-3483a601a8469c08Pharma Surgeen2026-07-25T00:00:00.000ZImplementation strategies used in clinical practice guidelines in older adults’ mental health and neurocognitive conditions: a scoping reviewhttps://www.pharmaradar360.com/article/clinical-similarity-economic-divergence-cost-effectiveness-and-population-health-03b77fe699463382Pharma Surgeen2026-07-25T00:00:00.000ZClinical similarity, economic divergence: cost-effectiveness and population health implications of dietary, pharmacological, and exercise interventions in older adults with type 2 diabetes: a secondary analysis of a randomized controlled trialhttps://www.pharmaradar360.com/article/supporting-high-quality-enrollment-decision-making-in-clinical-research-developm-1a2d6c2c5de63121Pharma Surgeen2026-07-25T00:00:00.000ZSupporting high-quality enrollment decision-making in clinical research: development of a novel informed consent communication framework and curriculumhttps://www.pharmaradar360.com/article/clinical-outcome-of-isolated-endoscopic-flexor-hallucis-longus-transfer-for-chro-0a69170bb876758ePharma Surgeen2026-07-25T00:00:00.000ZClinical Outcome of Isolated Endoscopic Flexor Hallucis Longus Transfer for Chronic Achilles Tendon Ruptures of Demanding Patientshttps://www.pharmaradar360.com/article/clinical-validation-of-photoplethysmography-based-finger-cuffless-blood-pressure-d790f0adc2657f4fPharma Surgeen2026-07-25T00:00:00.000ZClinical Validation of Photoplethysmography‐Based Finger Cuffless Blood Pressure Monitoring Following European Society of Hypertension Recommendationshttps://www.pharmaradar360.com/article/efficacy-safety-and-procedural-outcomes-of-pulsed-field-ablation-for-paroxysmal-78fd679a4f44707aPharma Surgeen2026-07-25T00:00:00.000ZEfficacy, Safety, and Procedural Outcomes of Pulsed‐Field Ablation for Paroxysmal Atrial Fibrillation: A Meta‐Analysishttps://www.pharmaradar360.com/article/preventing-constipation-in-people-living-with-dementia-co-design-of-a-non-pharma-c9544567d06f9891Pharma Surgeen2026-07-25T00:00:00.000ZPreventing Constipation in People Living With Dementia: Co‐Design of a Non‐Pharmacological Care Bundle for Residential Aged Carehttps://www.pharmaradar360.com/article/change-to-the-recognition-and-revision-of-target-problems-and-target-problem-pro-367d16bfe7119ffdPharma Surgeen2026-07-25T00:00:00.000ZChange to the recognition and revision of target problems and target problem procedures during eight‐session cognitive analytic therapy for self‐harmhttps://www.pharmaradar360.com/article/is-risk-based-screening-justified-by-the-wisdom-trial-69206843652241f7Pharma Surgeen2026-07-25T00:00:00.000ZIs Risk-based Screening Justified by the WISDOM Trial?https://www.pharmaradar360.com/article/hospital-at-home-vs-conventional-hospitalization-good-clinical-outcomes-with-low-683be1328c74bcbcPharma Surgeen2026-07-25T00:00:00.000ZHospital at Home vs conventional hospitalization: good clinical outcomes with lower cost and nosocomial complicationshttps://www.pharmaradar360.com/article/treatment-response-to-daratumumab-in-antibody-mediated-kidney-allograft-rejectio-3492ad433763cc99Pharma Surgeen2026-07-25T00:00:00.000ZTreatment response to daratumumab in antibody-mediated kidney allograft rejection (ABMR): evidence from serial protocol biopsieshttps://www.pharmaradar360.com/article/symmetrical-drug-related-intertriginous-and-flexural-exanthema-insights-from-fae-4a77788823777333Pharma Surgeen2026-07-25T00:00:00.000ZSymmetrical drug-related intertriginous and flexural exanthema: Insights from FAERS Databasehttps://www.pharmaradar360.com/article/temporal-mismatch-in-allogeneic-ipsc-therapies-biological-risks-and-implications-81d8f861410c63ffPharma Surgeen2026-07-25T00:00:00.000ZTemporal mismatch in allogeneic iPSC therapies: biological risks and implications for clinical translationhttps://www.pharmaradar360.com/article/future-directions-for-pharmaceutical-management-of-alopecia-areata-in-asia-043522de2b505d5dPharma Surgeen2026-07-25T00:00:00.000ZFuture directions for pharmaceutical management of alopecia areata in Asiahttps://www.pharmaradar360.com/article/commentary-on-electroacupuncture-for-essential-hypertension-mechanistic-insights-f4c0292b68871a8bPharma Surgeen2026-07-25T00:00:00.000ZCommentary on “Electroacupuncture for essential hypertension: mechanistic insights, current clinical evidence, and translational challenges”https://www.pharmaradar360.com/article/rosuvastatin-metformin-co-processing-enhanced-dissolution-oral-bioavailability-a-f6be2a1c598e927ePharma Surgeen2026-07-25T00:00:00.000ZRosuvastatin–metformin co-processing: enhanced dissolution, oral bioavailability, and therapeutic efficacy through a solvent-minimized approachhttps://www.pharmaradar360.com/article/qoq-med3-a-multimodal-reasoning-foundation-model-for-clinical-analysis-f6a560829d046aeaPharma Surgeen2026-07-25T00:00:00.000ZQoQ-Med3: a multimodal reasoning foundation model for clinical analysishttps://www.pharmaradar360.com/article/comparison-of-whole-genome-sequencing-with-clinical-targeted-panel-sequencing-of-8a3990326bbe3b08Pharma Surgeen2026-07-25T00:00:00.000ZComparison of whole genome sequencing with clinical targeted panel sequencing of metastatic prostate cancer: insights from real-world datahttps://www.pharmaradar360.com/article/the-effects-of-using-a-multi-modal-rest-cabin-versus-a-waitlist-control-on-worke-19a7bcdc14a9595dPharma Surgeen2026-07-25T00:00:00.000ZThe effects of using a multi-modal rest cabin versus a waitlist control on worker well-being: A pragmatic randomized controlled trialhttps://www.pharmaradar360.com/article/low-dose-baricitinib-plus-danazol-in-primary-immune-thrombocytopenia-a-randomize-ea02a13e59ad34d1Pharma Surgeen2026-07-25T00:00:00.000ZLow-dose baricitinib plus danazol in primary immune thrombocytopenia: a randomized, controlled phase 2 trialhttps://www.pharmaradar360.com/article/sialorrhea-outcomes-after-sublingual-atropine-in-neurogenic-disorders-evidence-f-45dd74c821568267Pharma Surgeen2026-07-25T00:00:00.000ZSialorrhea Outcomes After Sublingual Atropine in Neurogenic Disorders: Evidence From Randomized Controlled Trialshttps://www.pharmaradar360.com/article/vital-pulp-therapy-from-biological-foundations-to-contemporary-clinical-practice-add7bd036c3a92e8Pharma Surgeen2026-07-25T00:00:00.000ZVital Pulp Therapy: From Biological Foundations to Contemporary Clinical Practice with a Clinical Case Reporthttps://www.pharmaradar360.com/article/collaborating-for-affordable-patient-access-to-medicines-review-of-the-first-dec-6e59e380a6a0cb4cPharma Surgeen2026-07-25T00:00:00.000ZCollaborating for Affordable Patient Access to Medicines: Review of the First Decade of the Beneluxa Initiative in Pharmaceutical Policyhttps://www.pharmaradar360.com/article/extended-depth-of-field-intraocular-lens-for-cataract-after-vitrectomy-for-retin-7818a652b69ffd81Pharma Surgeen2026-07-25T00:00:00.000ZExtended Depth of Field Intraocular Lens for Cataract After Vitrectomy for Retinal Detachment: A Prospective Trialhttps://www.pharmaradar360.com/article/clinical-efficacy-of-a-12-pure-vitamin-c-serum-across-all-skin-phototypes-an-int-c28b95cc41963036Pharma Surgeen2026-07-25T00:00:00.000ZClinical Efficacy of a 12% Pure Vitamin C Serum Across All Skin Phototypes: An Integrated In Vitro–In Vivo Evaluationhttps://www.pharmaradar360.com/article/analysis-of-the-genetic-and-clinical-characteristics-of-18-pfapa-syndrome-patien-62bc5568bbd8420dPharma Surgeen2026-07-25T00:00:00.000ZAnalysis of the Genetic and Clinical Characteristics of 18 PFAPA Syndrome Patients in the Eastern Guangdong Province of Chinahttps://www.pharmaradar360.com/article/vaccine-based-cancer-immunotherapy-in-newly-diagnosed-glioblastoma-a-time-to-eve-bec93b063334f37aPharma Surgeen2026-07-25T00:00:00.000ZVaccine-based cancer immunotherapy in newly diagnosed glioblastoma: a time-to-event meta-analysis of phase II and III randomized controlled trialshttps://www.pharmaradar360.com/article/a-baseline-systemic-inflammatory-signature-predicts-anti-pd-1-response-in-advanc-d1373ef1619cf683Pharma Surgeen2026-07-25T00:00:00.000ZA baseline systemic inflammatory signature predicts anti-PD-1 response in advanced melanomahttps://www.pharmaradar360.com/article/liposomal-bupivacaine-in-perioperative-analgesia-a-comprehensive-review-of-clini-d114ae4401a138c4Pharma Surgeen2026-07-25T00:00:00.000ZLiposomal Bupivacaine in Perioperative Analgesia: A Comprehensive Review of Clinical Efficacy, Safety, and Economic Contexthttps://www.pharmaradar360.com/article/dna-repair-epigenetic-dysregulation-and-cytokine-network-crosstalk-in-head-and-n-bb2a8ae48253a93dPharma Surgeen2026-07-25T00:00:00.000ZDNA Repair, Epigenetic Dysregulation, and Cytokine Network Crosstalk in Head and Neck Cancer: Emerging Therapeutic Opportunities and Clinical Trialshttps://www.pharmaradar360.com/article/comparative-analysis-of-clinical-efficacy-safety-and-cosmetic-outcomes-of-modifi-c900e9263336f10aPharma Surgeen2026-07-25T00:00:00.000ZComparative Analysis of Clinical Efficacy, Safety, and Cosmetic Outcomes of Modified Bikini Line Laparoscopic Sleeve Gastrectomy (MBLSG) Versus Standard Laparoscopic Sleeve Gastrectomy (LSG): A Large-Series Studyhttps://www.pharmaradar360.com/article/comparative-immunoproteomic-profiling-of-malaysian-rice-varieties-mr219-mr269-an-93bd255f275c0d72Pharma Surgeen2026-07-25T00:00:00.000ZComparative immunoproteomic profiling of Malaysian rice varieties (MR219, MR269, and PadiU Putra) and their clinical reactivity in rice-allergic patientshttps://www.pharmaradar360.com/article/long-term-valve-durability-and-clinical-outcomes-after-transcatheter-versus-surg-96345ea8f376093fPharma Surgeen2026-07-25T00:00:00.000ZLong-term valve durability and clinical outcomes after transcatheter versus surgical aortic valve replacement in low-risk patients: a systematic review and meta-analysis of randomized trialshttps://www.pharmaradar360.com/article/a-simple-fluorescent-aptasensing-setup-controlled-by-hybridization-chain-reactio-48e8aeb84bc3fbdePharma Surgeen2026-07-25T00:00:00.000ZA Simple Fluorescent Aptasensing Setup Controlled by Hybridization Chain Reaction for Detection of Illegal Drug Methamphetamine: A Future Point-of-Care Testing Assayhttps://www.pharmaradar360.com/article/clinical-performance-of-a-segmented-refractive-multifocal-iol-visual-outcomes-ro-d7a6de6e0419f11bPharma Surgeen2026-07-25T00:00:00.000ZClinical performance of a segmented refractive multifocal IOL: visual outcomes, rotational stability, and the role of higher-order aberrationshttps://www.pharmaradar360.com/article/clinical-and-genetic-spectrum-of-genetic-eye-diseases-seen-in-two-newly-develope-5d2a7bf3a0df8505Pharma Surgeen2026-07-25T00:00:00.000ZClinical and genetic spectrum of genetic eye diseases seen in two newly developed ophthalmic genetics clinics: two-year experiencehttps://www.pharmaradar360.com/article/integrated-transcriptomic-analysis-identifies-an-akt1-associated-metabolic-infla-839628c56b64822aPharma Surgeen2026-07-25T00:00:00.000ZIntegrated transcriptomic analysis identifies an AKT1-associated metabolic-inflammatory signature in osteoporosishttps://www.pharmaradar360.com/article/impact-of-clinician-experience-on-the-accuracy-of-static-guided-implant-placemen-95c71ecd8f0190b3Pharma Surgeen2026-07-25T00:00:00.000ZImpact of clinician experience on the accuracy of static guided implant placement in post-extraction sockets: a cadaver studyhttps://www.pharmaradar360.com/article/tamponade-free-superior-ilm-flap-for-idiopathic-macular-hole-repair-a-pilot-stud-20d7493f7a85ab78Pharma Surgeen2026-07-25T00:00:00.000ZTamponade-free superior ILM flap for idiopathic macular hole repair: a pilot studyhttps://www.pharmaradar360.com/article/the-clinical-significance-of-flow-void-absence-following-endoscopic-third-ventri-f82b36d53dff431dPharma Surgeen2026-07-25T00:00:00.000ZThe clinical significance of flow void absence following endoscopic third ventriculostomy in asymptomatic patients: an ISPN-IFNE Surveyhttps://www.pharmaradar360.com/article/a-novel-topical-nitroglycerin-lidocaine-combination-for-procedural-pain-manageme-389fcfa5f504f313Pharma Surgeen2026-07-25T00:00:00.000ZA novel topical nitroglycerin-lidocaine combination for procedural pain management and rapid cannulation in neonates: results from a randomized controlled clinical trialhttps://www.pharmaradar360.com/article/multivariate-control-charts-based-on-mahalanobis-distance-for-bivariate-quality-6be08c229ed5033ePharma Surgeen2026-07-25T00:00:00.000ZMultivariate control charts based on Mahalanobis distance for bivariate quality monitoring in petrochemical and pharmaceutical analyseshttps://www.pharmaradar360.com/article/isorhamnetin-ameliorates-active-ulcerative-colitis-potentially-involving-the-nrf-b49d5a033d50ca46Pharma Surgeen2026-07-25T00:00:00.000ZIsorhamnetin ameliorates active ulcerative colitis potentially involving the Nrf2-PTGS2 axis: an integrative study from clinical evidence mining to in vivo validationhttps://www.pharmaradar360.com/article/optimal-unified-progressive-hybrid-censoring-for-log-logistic-reliability-models-99381e892df0c91dPharma Surgeen2026-07-25T00:00:00.000ZOptimal Unified Progressive Hybrid Censoring for Log‐Logistic Reliability Models: Applications in Engineering, Clinical, and Chemical Laboratorieshttps://www.pharmaradar360.com/article/brain-age-prediction-in-autism-translating-imaging-biomarkers-without-overstatin-f6076d3909014570Pharma Surgeen2026-07-25T00:00:00.000ZBrain‐age prediction in autism: Translating imaging biomarkers without overstating clinical meaninghttps://www.pharmaradar360.com/article/machine-learning-prediction-of-hoehn-and-yahr-scores-at-5-years-post-scp-sup-123-6d6960dc14018e26Pharma Surgeen2026-07-25T00:00:00.000ZMachine Learning Prediction of Hoehn and Yahr Scores at 5‐Years Post‐ <scp> ¹²³ I </scp> ‐Ioflupane <scp>SPECT</scp> Imaging in a Real‐World Parkinson's Disease Datasethttps://www.pharmaradar360.com/article/toward-autonomous-clinics-human-robot-collaboration-in-clinical-care-1887d2a5ad52ef17Pharma Surgeen2026-07-25T00:00:00.000ZToward Autonomous Clinics: Human–Robot Collaboration in Clinical Carehttps://www.pharmaradar360.com/article/epilepsy-of-infancy-with-migrating-focal-seizures-in-scp-rars2-scp-related-disea-469ea4ea2106f5f2Pharma Surgeen2026-07-25T00:00:00.000ZEpilepsy of infancy with migrating focal seizures in <scp>RARS2</scp> ‐related disease: Expanding the clinical spectrumhttps://www.pharmaradar360.com/article/acute-encephalopathy-in-a-patient-with-chronic-isotretinoin-exposure-and-frequen-74fb20ed60afc2ddPharma Surgeen2026-07-25T00:00:00.000ZAcute Encephalopathy in a Patient With Chronic Isotretinoin Exposure and Frequent Rizatriptan Use: A Case Reporthttps://www.pharmaradar360.com/article/incidental-colonic-pneumatosis-intestinalis-with-pneumoperitoneum-managed-conser-fcc7d4a71318098ePharma Surgeen2026-07-25T00:00:00.000ZIncidental Colonic Pneumatosis Intestinalis With Pneumoperitoneum Managed Conservativelyhttps://www.pharmaradar360.com/article/intracerebral-hemorrhage-induces-monocyte-scp-tnf-scp-signaling-in-patients-that-f8d6f5b777c8b432Pharma Surgeen2026-07-25T00:00:00.000ZIntracerebral Hemorrhage Induces Monocyte <scp>TNF</scp> Signaling in Patients That Is Suppressed by <scp>BAF</scp> 312https://www.pharmaradar360.com/article/determining-parental-factors-for-clinical-trial-attrition-in-pediatric-acute-lym-6c0a01cade43cf26Pharma Surgeen2026-07-25T00:00:00.000ZDetermining Parental Factors for Clinical Trial Attrition in Pediatric Acute Lymphoblastic Leukemiahttps://www.pharmaradar360.com/article/hub-101-taiwan-biotech-looks-to-level-up-83f05af90995d579Pharma Surgeen2026-07-24T23:57:00.000ZHub 101: Taiwan biotech looks to level uphttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-inc-wst-a-bargain-after-7-7-d-e4d21db88236d99bPharma Surgeen2026-07-24T23:39:41.000ZIs West Pharmaceutical Services Inc (WST) a Bargain After 7.7% Dhttps://www.pharmaradar360.com/article/tian-an-pharmaceutical-co-ltd-revenue-breakdown-otc-tnph-907aef5e1f3b57b9Pharma Surgeen2026-07-24T23:39:14.000ZTian'an Pharmaceutical Co., Ltd. Revenue Breakdown – OTC:TNPHhttps://www.pharmaradar360.com/article/14-new-weight-loss-drugs-8f97f67645d6c678Pharma Surgeen2026-07-24T23:35:24.000Z14 New Weight Loss Drugshttps://www.pharmaradar360.com/article/hai-phong-pharmaceutical-joint-stock-co-revenue-breakdown-upcom-dph-1c4769c7f7411436Pharma Surgeen2026-07-24T23:08:02.000ZHai Phong Pharmaceutical Joint Stock Co Revenue Breakdown – UPCOM:DPHhttps://www.pharmaradar360.com/article/big-pharma-s-patent-cliff-meets-a-new-biotech-cold-war-we-need-to-outrun-china-n-d5a74b2c5703436fPharma Surgeen2026-07-24T23:06:13.000ZBig pharma's patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw ithttps://www.pharmaradar360.com/article/kolon-tissuegene-braces-for-100-mn-redemption-calls-on-convertible-bonds-adbca1daa4f87ad2Pharma Surgeen2026-07-24T23:04:44.000ZKolon TissueGene braces for $100 mn redemption calls on convertible bondshttps://www.pharmaradar360.com/article/chugai-pharmaceutical-chgcf-reports-strong-first-half-earnings-381d313f05e9dee4Pharma Surgeen2026-07-24T23:03:45.000ZChugai Pharmaceutical (CHGCF) Reports Strong First Half Earningshttps://www.pharmaradar360.com/article/wanbangde-pharmaceutical-holding-group-co-ltd-class-a-revenue-breakdown-szse-002-33075cc3b98630ddPharma Surgeen2026-07-24T22:59:08.000ZWanbangde Pharmaceutical Holding Group Co., Ltd. Class A Revenue Breakdown – SZSE:002082https://www.pharmaradar360.com/article/jeil-pharmaceutical-co-ltd-revenue-breakdown-krx-271980-cf5bcab1da9e71a6Pharma Surgeen2026-07-24T22:58:55.000ZJeil Pharmaceutical Co. Ltd. Revenue Breakdown – KRX:271980https://www.pharmaradar360.com/article/why-shattuck-labs-stock-flew-nearly-5-higher-on-friday-300c403e91be63dbPharma Surgeen2026-07-24T22:54:32.000ZWhy Shattuck Labs Stock Flew Nearly 5% Higher on Fridayhttps://www.pharmaradar360.com/article/fda-advisers-narrowly-vote-to-add-6-peptides-to-a-drug-compounding-list-what-s-n-05eb0af1ede61b6fPharma Surgeen2026-07-24T22:50:19.000ZFDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?https://www.pharmaradar360.com/article/hims-hers-health-repligen-west-pharmaceutical-services-and-10x-genomics-stocks-t-e69e4e9dfeea6e06Pharma Surgeen2026-07-24T22:49:08.000ZHims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Knowhttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-inc-wst-a-bargain-after-7-7-d-15020f1187a22828Pharma Surgeen2026-07-24T22:30:00.000ZIs West Pharmaceutical Services Inc (WST) a Bargain After 7.7% Dhttps://www.pharmaradar360.com/article/us-judge-says-biden-era-restrictions-on-prescribing-abortion-drug-are-unlawful-55a4575a0a7fe2f1Pharma Surgeen2026-07-24T22:25:30.000ZUS judge says Biden-era restrictions on prescribing abortion drug are unlawfulhttps://www.pharmaradar360.com/article/edesa-biotech-inc-revenue-breakdown-nasdaq-edsa-276a4b97bd47b925Pharma Surgeen2026-07-24T22:22:06.000ZEdesa Biotech, Inc. Revenue Breakdown – NASDAQ:EDSAhttps://www.pharmaradar360.com/article/fda-advisers-recommend-relaxing-us-rules-on-compounding-peptides-35c4be0e1373d710Pharma Surgeen2026-07-24T22:14:31.000ZFDA advisers recommend relaxing US rules on compounding peptideshttps://www.pharmaradar360.com/article/vytrus-biotech-sa-revenue-breakdown-tradegate-v5p-c662038a6a9dc0abPharma Surgeen2026-07-24T21:50:28.000ZVytrus Biotech SA Revenue Breakdown – TRADEGATE:V5Phttps://www.pharmaradar360.com/article/baxter-issues-voluntary-nationwide-recall-of-cefazolin-in-dextrose-injection-usp-9a77da71435eb927Pharma Surgeen2026-07-24T21:46:43.000ZBAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTIONhttps://www.pharmaradar360.com/article/veraxa-biotech-shareholders-approve-all-proposals-at-extraordinary-general-meeti-233f990f1ca22f84Pharma Surgeen2026-07-24T21:31:21.000ZVeraxa Biotech Shareholders Approve All Proposals At Extraordinary General Meeting, Strengthening Strategic Flexibility For Future Growthhttps://www.pharmaradar360.com/article/amgen-submits-new-data-to-challenge-fda-s-proposal-to-withdraw-tavneos-5d1a2edec8218146Pharma Surgeen2026-07-24T21:26:44.000ZAmgen submits new data to challenge FDA's proposal to withdraw Tavneoshttps://www.pharmaradar360.com/article/pandora-s-box-fda-peptide-votes-could-open-the-door-to-more-unproven-drugs-4a4937ec5c9035eePharma Surgeen2026-07-24T21:17:44.000Z‘Pandora’s box’: FDA peptide votes could open the door to more unproven drugshttps://www.pharmaradar360.com/article/an-fda-committee-just-voted-in-favor-of-peptides-despite-the-agency-s-opposition-9a77905bc2d90a05Pharma Surgeen2026-07-24T20:52:38.000ZAn FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Oppositionhttps://www.pharmaradar360.com/article/a-u-s-review-panel-recommended-loosening-restrictions-on-multiple-trendy-peptide-b20546e50de7fff1Pharma Surgeen2026-07-24T20:52:23.000ZA U.S. review panel recommended loosening restrictions on multiple trendy peptides, endorsing proposals that specialized pharmacies be allowed to produce such substances despite alarm bells from medical experts over safety concerns. | via ANC 24/7 Fullhttps://www.pharmaradar360.com/article/amgen-sheds-around-40-staffers-as-struggles-mount-2c09a45f47da405cPharma Surgeen2026-07-24T20:45:34.000ZAmgen sheds around 40 staffers as struggles mounthttps://www.pharmaradar360.com/article/oncolytics-biotech-disclosed-failure-to-satisfy-a-continued-listing-rule-or-stan-3ec9c2085d1baae5Pharma Surgeen2026-07-24T20:43:01.000ZOncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standardhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-underperforms-friday-when-compared-to-com-7e37365bc0be1e2cPharma Surgeen2026-07-24T20:30:00.000ZWest Pharmaceutical Services Inc. stock underperforms Friday when compared to competitorshttps://www.pharmaradar360.com/article/fierce-biotech-hires-russo-as-a-reporter-777dba9874c1511ePharma Surgeen2026-07-24T20:29:33.000ZFierce Biotech hires Russo as a reporterhttps://www.pharmaradar360.com/article/lilly-s-triple-agonist-just-became-its-most-powerful-obesity-drug-yet-3ba531e53c983e04Pharma Surgeen2026-07-24T20:29:30.000ZLilly's triple agonist just became its most powerful obesity drug yethttps://www.pharmaradar360.com/article/veraxa-biotech-shareholders-approve-governance-changes-baee15e8cbaa329bPharma Surgeen2026-07-24T20:26:06.000ZVeraxa Biotech shareholders approve governance changeshttps://www.pharmaradar360.com/article/fda-advisers-say-six-popular-peptides-can-be-compounded-here-are-the-issues-they-d2c956ca89111380Pharma Surgeen2026-07-24T20:26:00.000ZFDA advisers say six popular peptides can be compounded. Here are the issues they considered.https://www.pharmaradar360.com/article/chunghwa-chemical-synthesis-biotech-co-ltd-class-a-revenue-breakdown-twse-1762-0de839250656a084Pharma Surgeen2026-07-24T20:20:48.000ZChunghwa Chemical Synthesis & Biotech Co., Ltd. Class A Revenue Breakdown – TWSE:1762https://www.pharmaradar360.com/article/fugitive-wanted-for-sexual-assault-allegedly-spent-20-years-on-the-run-lived-as-6d30a75d35dd08bcPharma Surgeen2026-07-24T20:00:00.000ZFugitive wanted for sexual assault allegedly spent 20 years on the run, lived as biotech executivehttps://www.pharmaradar360.com/article/ahn-gook-pharmaceutical-co-ltd-revenue-breakdown-krx-001540-01a836770e41879fPharma Surgeen2026-07-24T19:59:39.000ZAHN-GOOK PHARMACEUTICAL Co., Ltd. Revenue Breakdown – KRX:001540https://www.pharmaradar360.com/article/missed-ai-memory-bull-run-biotech-may-be-the-next-breakout-trade-but-retail-sent-671bce17695a553aPharma Surgeen2026-07-24T19:56:28.000ZMissed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lowerhttps://www.pharmaradar360.com/article/conditional-activation-of-il-12-through-a-fibronectin-edb-dependent-switch-gate-479854fd779d8bccPharma Surgeen2026-07-24T19:45:01.000ZConditional activation of IL-12 through a Fibronectin-EDB dependent switch gatehttps://www.pharmaradar360.com/article/assessing-cross-version-simcyp-simulator-prediction-performance-using-a-bioequiv-ae3b629ab3295affPharma Surgeen2026-07-24T19:41:28.000ZAssessing Cross-Version Simcyp Simulator Prediction Performance Using a Bioequivalence Framework to Support EMA Qualificationhttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-enxtpa-dim-stock-faces-rich-p-e-as-margins-improve-to-9-4593c49df4c90465Pharma Surgeen2026-07-24T19:31:36.000ZSartorius Stedim Biotech (ENXTPA:DIM) Stock Faces Rich P/E As Margins Improve To 9.7%https://www.pharmaradar360.com/article/sartorius-stedim-biotech-enxtpa-dim-stock-faces-rich-p-e-as-margins-improve-to-9-927a766da830ae94Pharma Surgeen2026-07-24T19:31:35.000ZSartorius Stedim Biotech (ENXTPA:DIM) Stock Faces Rich P/E As Margins Improve To 9.7%https://www.pharmaradar360.com/article/ono-pharmaceutical-co-ltd-unsponsored-adr-revenue-breakdown-mun-on40-ae1d9a8434feaf9ePharma Surgeen2026-07-24T19:20:29.000ZOno Pharmaceutical Co., Ltd. Unsponsored ADR Revenue Breakdown – MUN:ON40https://www.pharmaradar360.com/article/legend-biotech-shares-fall-after-ubs-downgrade-88bca6cf302a4944Pharma Surgeen2026-07-24T19:16:45.000ZLegend Biotech Shares Fall After UBS Downgradehttps://www.pharmaradar360.com/article/binh-dinh-pharmaceutical-medical-equipment-jsc-revenue-breakdown-hose-dbd-25d07dd4cd0b9c4bPharma Surgeen2026-07-24T19:06:53.000ZBinh Dinh Pharmaceutical & Medical Equipment JSC Revenue Breakdown – HOSE:DBDhttps://www.pharmaradar360.com/article/fda-advisers-recommend-against-the-first-unapproved-peptide-on-second-day-of-mee-4b5d13e0f86da78aPharma Surgeen2026-07-24T19:00:39.000ZFDA advisers recommend against the first unapproved peptide on second day of meetinghttps://www.pharmaradar360.com/article/price-to-sales-forward-of-nkgen-biotech-inc-otc-nkgn-ee4b6b0917c55340Pharma Surgeen2026-07-24T18:48:12.000ZPrice to sales forward of NKGen Biotech Inc. – OTC:NKGNhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-nkgen-biotech-inc-otc-nkgn-c19f773049432553Pharma Surgeen2026-07-24T18:47:25.000ZEnterprise value to EBITDA forward of NKGen Biotech Inc. – OTC:NKGNhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-nkgen-biotech-inc-otc-nkgn-3e1e373c01931923Pharma Surgeen2026-07-24T18:45:08.000ZEnterprise value to revenue forward of NKGen Biotech Inc. – OTC:NKGNhttps://www.pharmaradar360.com/article/price-to-book-forward-of-nkgen-biotech-inc-otc-nkgn-b4e1417a945720dbPharma Surgeen2026-07-24T18:41:17.000ZPrice to book forward of NKGen Biotech Inc. – OTC:NKGNhttps://www.pharmaradar360.com/article/fda-advisers-recommend-against-the-first-unapproved-peptide-on-second-day-of-mee-7293483178ccda8bPharma Surgeen2026-07-24T18:33:21.000ZFDA advisers recommend against the first unapproved peptide on second day of meetinghttps://www.pharmaradar360.com/article/passaparola-periodo-estivo-2026-sportelli-e-altri-servizi-sempre-aperti-9bb5a19657dfe4aePharma Surgeen2026-07-24T18:30:00.000Z#PASSAPAROLA. Periodo estivo 2026: sportelli e altri servizi sempre apertihttps://www.pharmaradar360.com/article/veraxa-biotech-ag-vrxa-appoints-christoph-erkel-as-chief-scientific-officer-c6b6ebc3313dbb90Pharma Surgeen2026-07-24T18:30:00.000ZVERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officerhttps://www.pharmaradar360.com/article/federal-judge-rules-that-fda-s-mifepristone-restrictions-are-excessive-unscienti-f1ff8549aecf6518Pharma Surgeen2026-07-24T18:27:00.000ZFederal Judge Rules That FDA’s Mifepristone Restrictions Are Excessive, Unscientific and Unlawfulhttps://www.pharmaradar360.com/article/fda-panel-narrowly-backs-peptide-drug-touted-by-joe-rogan-and-other-influencers-40d4e6bdd138a2b9Pharma Surgeen2026-07-24T18:26:00.000ZFDA panel narrowly backs peptide drug touted by Joe Rogan and other influencershttps://www.pharmaradar360.com/article/eastgate-biotech-corp-revenue-breakdown-otc-etbi-5f7ea003a345f30dPharma Surgeen2026-07-24T18:23:21.000ZEASTGATE BIOTECH CORP Revenue Breakdown – OTC:ETBIhttps://www.pharmaradar360.com/article/dhg-pharmaceutical-joint-stock-company-revenue-breakdown-hose-dhg-069f845714d4e09cPharma Surgeen2026-07-24T18:22:21.000ZDHG Pharmaceutical Joint Stock Company Revenue Breakdown – HOSE:DHGhttps://www.pharmaradar360.com/article/us-judge-says-biden-era-restrictions-on-prescribing-abortion-drug-are-unlawful-c72df22b833e9184Pharma Surgeen2026-07-24T18:19:49.000ZUS judge says Biden-era restrictions on prescribing abortion drug are unlawfulhttps://www.pharmaradar360.com/article/fda-approves-tylenol-with-naproxen-otc-b663371cc43691c1Pharma Surgeen2026-07-24T18:08:45.000ZFDA approves Tylenol with Naproxen OTChttps://www.pharmaradar360.com/article/why-is-intellia-therapeutics-ntla-a-battleground-stock-with-38-short-interest-ac440ef295d82fe1Pharma Surgeen2026-07-24T18:07:31.000ZWhy is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interesthttps://www.pharmaradar360.com/article/fda-advisers-dismiss-safety-warnings-back-four-peptide-treatments-ef502c19fa9d7e53Pharma Surgeen2026-07-24T18:00:09.000ZFDA advisers dismiss safety warnings, back four peptide treatmentshttps://www.pharmaradar360.com/article/peptide-adcomm-day-2-emideltide-voted-down-in-panel-s-1st-pushback-f9cd9855155110a5Pharma Surgeen2026-07-24T18:00:00.000ZPeptide adcomm Day 2: Emideltide voted down in panel's 1st pushbackhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-limited-teva-stock-price-news-quote-and-history-fc990b185865c912Pharma Surgeen2026-07-24T17:58:15.000ZTeva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/american-heart-association-champion-returns-to-lead-board-and-drive-impact-acros-925d48681801ef14Pharma Surgeen2026-07-24T17:58:00.000ZAmerican Heart Association champion returns to lead board and drive impact across the Southeast regionhttps://www.pharmaradar360.com/article/the-american-diabetes-association-applauds-the-preservation-of-medicaid-coverage-e784da1bcfaa4b91Pharma Surgeen2026-07-24T17:52:27.000ZThe American Diabetes Association Applauds the Preservation of Medicaid Coverage for FDA-Approved Obesity Medications in North Carolinahttps://www.pharmaradar360.com/article/mmi-trailblazers-alum-is-a-ray-of-light-at-uno-job-9cfb0b4a771db42ePharma Surgeen2026-07-24T17:48:15.000ZMMI Trailblazers alum is ‘a ray of light’ at UNO jobhttps://www.pharmaradar360.com/article/aurobindo-pharma-inks-licensing-deal-with-merck-for-hiv-drug-741dcc7ecdb35b42Pharma Surgeen2026-07-24T17:38:21.000ZAurobindo Pharma Inks Licensing Deal With Merck For HIV Drughttps://www.pharmaradar360.com/article/de-la-plata-al-mundo-el-satelite-usat-1-de-la-unlp-ya-inicio-su-camino-hacia-el-ff229d860ca5623bPharma Surgeen2026-07-24T17:37:52.000ZDe La Plata al mundo: el satélite USAT 1 de la UNLP ya inició su camino hacia el espaciohttps://www.pharmaradar360.com/article/cordis-project-guide-ai-guiding-your-treatment-with-current-evidence-bca7913ab8edc08fPharma Surgeen2026-07-24T17:36:09.000ZCORDIS project: GUIDE-AI – Guiding your treatment with current evidencehttps://www.pharmaradar360.com/article/cordis-project-regenerative-medicine-and-advanced-medicinal-therapeutic-products-9a0a1aedb4ad104aPharma Surgeen2026-07-24T17:36:04.000ZCORDIS project: Regenerative Medicine and Advanced Medicinal Therapeutic Products United for PhD excellencehttps://www.pharmaradar360.com/article/cordis-project-gender-language-and-epistemicide-in-reproductive-healthcare-01b80c6dfac03767Pharma Surgeen2026-07-24T17:36:02.000ZCORDIS project: Gender, Language and Epistemicide in Reproductive Healthcarehttps://www.pharmaradar360.com/article/mas-infraestructura-para-ciencias-veterinarias-55a5596590f1e9ffPharma Surgeen2026-07-24T17:31:51.000ZMás infraestructura para Ciencias Veterinariashttps://www.pharmaradar360.com/article/estudiantes-ganaron-un-certamen-internacional-de-geociencias-e-ingenieria-fe44871817422c7fPharma Surgeen2026-07-24T17:31:24.000ZEstudiantes ganaron un certamen internacional de geociencias e ingenieríahttps://www.pharmaradar360.com/article/atletas-de-la-unlp-representaran-a-argentina-en-los-juegos-universitarios-americ-6e8cfd07315abafaPharma Surgeen2026-07-24T17:30:52.000ZAtletas de la UNLP representarán a Argentina en los Juegos Universitarios Americanoshttps://www.pharmaradar360.com/article/biotech-companies-are-being-reshaped-by-ai-01b247ca3cd11ed2Pharma Surgeen2026-07-24T17:27:33.000ZBiotech companies are being reshaped by AIhttps://www.pharmaradar360.com/article/chugai-pharmaceutical-revenue-and-profit-surged-in-h1-fy-2026-with-strong-sales-c0967d5df6035606Pharma Surgeen2026-07-24T17:25:20.000ZChugai Pharmaceutical : Revenue and profit surged in H1 FY 2026, with strong sales, robust pipeline, and record filingshttps://www.pharmaradar360.com/article/fda-votes-to-reduce-restrictions-on-four-peptides-pharmexec-e8fcaf5f4f6fa24cPharma Surgeen2026-07-24T17:20:51.000ZFDA Votes to Reduce Restrictions on Four Peptides | PharmExechttps://www.pharmaradar360.com/article/shanghai-fosun-pharmaceutical-group-co-ltd-class-h-revenue-breakdown-fwb-08hh-5f932f3836def0c9Pharma Surgeen2026-07-24T17:20:00.000ZShanghai Fosun Pharmaceutical (Group) Co., Ltd. Class H Revenue Breakdown – FWB:08HHhttps://www.pharmaradar360.com/article/etfs-investing-in-zhejiang-jingxin-pharmaceutical-co-ltd-class-a-stocks-2eaccb946ae806f2Pharma Surgeen2026-07-24T17:16:15.000ZETFs Investing in Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/pharmacyte-biotech-inc-revenue-breakdown-nasdaq-pmcb-18c0c5340a0c2344Pharma Surgeen2026-07-24T17:06:03.000ZPharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCBhttps://www.pharmaradar360.com/article/zhejiang-east-asia-pharmaceutical-co-ltd-class-a-revenue-breakdown-sse-605177-8b4180074bb87e1bPharma Surgeen2026-07-24T17:05:32.000ZZhejiang East Asia Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SSE:605177https://www.pharmaradar360.com/article/state-policies-on-abortion-coverage-in-medicaid-private-insurance-and-aca-exchan-71a178e829fcff21Pharma Surgeen2026-07-24T17:04:22.000ZState Policies on Abortion Coverage in Medicaid, Private Insurance, and ACA Exchange Plans in 2025https://www.pharmaradar360.com/article/jubilant-biosys-brings-together-global-biotech-leaders-to-advance-the-future-of-072be0f15bfdb5a6Pharma Surgeen2026-07-24T17:00:00.000ZJubilant Biosys Brings Together Global Biotech Leaders to Advance the Future of Healthcare Innovation at 2nd EDGE Innovation Forumhttps://www.pharmaradar360.com/article/aurobindo-pharma-enters-non-exclusive-license-agreement-with-msd-cf199aeaa0a92ef3Pharma Surgeen2026-07-24T16:49:18.000ZAurobindo Pharma Enters Non-Exclusive License Agreement With MSDhttps://www.pharmaradar360.com/article/veraxa-biotech-ag-nasdaq-vrxa-appoints-christoph-erkel-as-chief-scientific-offic-a838d84d7cec183fPharma Surgeen2026-07-24T16:38:56.000ZVERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officerhttps://www.pharmaradar360.com/article/a-semester-with-work-it-reflections-from-our-assistants-798ae174d8b0482cPharma Surgeen2026-07-24T16:32:01.000ZA Semester with WORK-IT: Reflections from our assistantshttps://www.pharmaradar360.com/article/chugai-pharmaceutical-chgcf-reports-strong-first-half-earnings-5dbcd1332ce12170Pharma Surgeen2026-07-24T16:30:00.000ZChugai Pharmaceutical (CHGCF) Reports Strong First Half Earningshttps://www.pharmaradar360.com/article/african-pharma-giants-secure-deal-for-merck-s-monthly-hiv-pill-b6b078ce7f41c7b7Pharma Surgeen2026-07-24T16:27:17.000ZAfrican pharma giants secure deal for Merck’s monthly HIV pill